Pharmacokinetics of a pediatric tribendimidine dose-finding study to treat hookworm infection in african children

Abstract

Tribendimidine is a broad-spectrum anthelminthic available in China, which is currently being pursued for U.S. Food and Drug Administration approval for soil-transmitted helminth infections. Pharmacokinetic (PK) studies with tribendimidine in children, the main target group for treatment programs, have not been conducted to date. In the framework of a dose-ranging study in hookworm-infected school-aged children in Côte d’Ivoire, children were treated with either 100, 200, or 400 mg tribendimidine. Dried blood spot samples were collected up to 22 h after treatment. The active metabolite, deacetylated amidantel (dADT) and its metabolite acylated dADT (adADT) were quantified using liquid chromatography tandem mass spectrometry. PK parameters were calculated using a noncompartmental model, and univariate logistic regression was applied using maximal blood concentrations (C max ) and area under the blood concentration-time curve for 0 to 22 h (AUC 0–22 ) as predictors of drug efficacy. Dried blood spot samples of 101 children were analyzed. We observed a less than proportional and proportional exposure in dADT’s median C max and AUC 0–22 , respectively, following administration of 100 mg (C max 853 ng/ml; AUC 0–22 3,019 h · ng/ml) and 400 mg (C max 2,275 ng/ml; AUC 0–22 12,530 h · ng/ml) tribendimidine. There were large, dose-independent variations in the time to C max (T max ) and ratios of dADT to adADT. We did not detect an influence of C max or AUC 0–22 of dADT or adADT on drug efficacy or adverse events. Since our study population was bearing hookworm infection of mainly low intensity, additional studies with heavy intensity infections might be required to confirm this observation.